LAB282 accelerates Oxford University’s life sciences with second round of awards
Drugs from bugs tops list of LAB282's first round of grants
LAB282, the drug discovery partnership for Oxford University, has made its second round of awards to support promising life sciences ideas with market potential emerging from the University.
Out of a potential seven candidates, LAB282 decided to support five with awards ranging into six-figure sums.
LAB282 – accelerating drug discovery at Oxford
Oxford University and Evotec’s drug discovery partnership launched last year to quickly accelerate drugs to market begins making awards, backing projects targeting cardiovascular and infectious diseases.
Oxford University, Oxford University Innovation, Oxford Sciences Innovation and Evotec announce a new partnership to advance the development of next-generation medicines arising from Oxford research.